IP Library › Granted Patent US 12,502,389
Granted Patent B2
US 12,502,389 · App. 18/368,208 · Granted Dec 23, 2025

Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidine

Inventors: Jaikrishna Patel (Cary, NC); Paul Chamberlin (Brookline, MA)
Assignee: IMBRIA PHARMACEUTICALS, INC.
A61K31/496A61K9/0053A61P9/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,502,389
App. No.
18/368,208
Granted
Dec 23, 2025
Kind
B2
Abstract

The invention provides methods of treatment of heart failure with preserved ejection fraction (HFpEF) using modified forms of trimetazidine, such as CV-8972 and CV-8814.

Claims (22)

1 . A method of treating left ventricular ejection fraction (LVEF) of greater than 50% in a subject, the method comprising providing to a subject having LVEF greater than 50% a compound represented by formula (X):

or a pharmaceutically acceptable salt thereof.

2 . The method of claim 1 , wherein the LVEF greater than 50% is associated with a condition selected from the group consisting of hypertension, obesity, and diabetes.

3 . The method of claim 1 , wherein the compound is provided in a pharmaceutical composition.

4 . The method of claim 3 , wherein the pharmaceutical composition is provided orally.

5 . The method of claim 4 , wherein the composition comprises a format selected from the group consisting of a tablet, troche, lozenge, aqueous suspension, oily suspension, emulsion, hard capsule, soft capsule, and syrup.

6 . The method of claim 3 , wherein the pharmaceutical composition comprises a mixture of the compound and an erodible polymer that promotes swelling of the mixture in an aqueous environment.

7 . The method of claim 6 , wherein the erodible polymer is hydroxypropyl methylcellulose (HPMC).

8 . The method of claim 7 , wherein the mixture comprises the compound and HPMC in a ratio of from about 1:10 to about 10:1.

9 . The method of claim 3 , wherein the pharmaceutical composition is a unit dosage comprising from about 10 mg to about 500 mg of the compound.

10 . The method of claim 3 , wherein the pharmaceutical composition comprises a crystal comprising a Form A polymorph of the compound.

11 . The method of claim 10 , wherein the crystal comprises a hydrochloride salt of the compound.

12 . A method of treating left ventricular ejection fraction (LVEF) of greater than 50% in a subject, the method comprising providing to a subject having LVEF greater than 50% a compound represented by formula (IX):

or a pharmaceutically acceptable salt thereof.

13 . The method of claim 12 , wherein the LVEF greater than 50% is associated with a condition selected from the group consisting of hypertension, obesity, and diabetes.

14 . The method of claim 12 , wherein the compound is provided in a pharmaceutical composition.

15 . The method of claim 14 , wherein the pharmaceutical composition is provided orally.

16 . The method of claim 15 , wherein the composition comprises a format selected from the group consisting of a tablet, troche, lozenge, aqueous suspension, oily suspension, emulsion, hard capsule, soft capsule, and syrup.

17 . The method of claim 14 , wherein the pharmaceutical composition comprises a mixture of the compound and an erodible polymer that promotes swelling of the mixture in an aqueous environment.

18 . The method of claim 17 , wherein the erodible polymer is hydroxypropyl methylcellulose (HPMC).

19 . The method of claim 18 , wherein the mixture comprises the compound and HPMC in a ratio of from about 1:10 to about 10:1.

20 . The method of claim 14 , wherein the pharmaceutical composition is a unit dosage comprising from about 10 mg to about 500 mg of the compound.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2023
From: PATEL, JAIKRISHNA; CHAMBERLIN, PAUL
To: IMBRIA PHARMACEUTICALS, INC.
Reel/Frame 065886/0342 →
Continuity (3)
Continuation 17540653 · Dec 2, 2021
Provisional Application 63123715 · Dec 10, 2020
Related Publication 20240000775A1 · Jan 4, 2024
References Cited (34)
US 4100285A · Murai et al. · 1978 [cited by applicant]
US 4166452A · Generales, Jr. · 1979 [cited by applicant]
US 4256108A · Theeuwes · 1981 [cited by applicant]
US 4265874A · Bonsen et al. · 1981 [cited by applicant]
US 4574156A · Morita et al. · 1986 [cited by applicant]
US 6214841B1 · Jackson et al. · 2001 [cited by applicant]
US 10556013B2 · Levin · 2020 [cited by applicant]
US 10953102B2 · Levin · 2021 [cited by applicant]
US 11376330B2 · Levin · 2022 [cited by applicant]
US 11793807B2 · Patel · 2023 [cited by examiner]
US 20030232877A1 · Sikorski et al. · 2003 [cited by applicant]
US 20090012096A1 · Gu et al. · 2009 [cited by applicant]
US 20170348292A1 · Kaye · 2017 [cited by applicant]
US 20180360975A1 · Levin · 2018 [cited by examiner]
US 20190117623A1 · Simpson, Jr. et al. · 2019 [cited by applicant]
WO 2020081361A1 · 2020 [cited by applicant]
WO 2020243119A1 · 2020 [cited by applicant]
WO 2020247213A1 · 2020 [cited by applicant]
Heart failure with preserved ejection fraction Harper et al. Clinical Medicine 2018 vol. 18, No. 2: s24-s9 (Year: 2018). [cited by examiner]
Albakri, 2018, Hypertrophic cardiomyopathy: A review of literature on clinical status and meta-analysis of diagnosis and clinical management methods, Clin Med Invest 3(2):1-16. [cited by applicant]
Antunes, 2020, Hypertrophic cardiomyopathy, Int J Cardiol Heart Vasc, 27:100503, 12 pages. [cited by applicant]
Chamberlin, 2021, A Novel First-In Class Partial Fatty Acif Oxidation Inhibitor Improves Cardiac Remodeling and Function Post-Myocardial Infarction, Journal of the American College of Cardiology, 77(18):539. [cited by applicant]
Egbuche, 2020, Contemporary Pharmacologic Management of Heart Failure with Reduced Ejection Fraction: A Review, Curr Cardiol Rev, 16(1):55-64. [cited by applicant]
Harding, 2021, An Investigational Agent Designed to Augment Cardiac Glucose Utilization and Energetics Reduces Cardiac Remodelling and Preserves Cardiac Function in a Model of Pressure Overload-Induced Heart Failure, Me… [cited by applicant]
Hinder, 2018, Developing Drugs for Heart Failure With Reduced Ejection Fraction: What HAve We Learned From Clinical Trials?, Clin Pharmacol Ther, 103(5):802-814. [cited by applicant]
International Search Report and Written Opinionn issued in International Application No. PCT/US2021/061583, date of mailing: Apr. 21, 2022, 16 pages. [cited by applicant]
Kloner, 2020, Stunned and Hibernating Myocardium: Where Are We Nearly 4 Decades Later?, J Am Heart Assoc, 9(3):e015502, 11 pages. [cited by applicant]
Ma, 2020, Heart failure with preserved ejection fraction: an update on pathophysiology, diagnosis, treatment, and prognosis, Braz J Med Biol Res, 53(7):e9646, 16 pages. [cited by applicant]
Maron, 2017, Nonobstructive Hypertrophic Cardiomyopathy Out of the Shadows: Known from the Beginning but Largely Ignored, Until Now, Am J Med, 130(2):119-123. [cited by applicant]
Murphy, 2020, Heart Failure With Reduced Ejection Fraction: A Review, JAMA, 324(5):488-504. [cited by applicant]
Prinz, 2011, The diagnosis and treatment of hypertrophic cardiomypathy, Dtsch Arztebl Int, 108(13):209-215. [cited by applicant]
Reed, 2015, A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF), Curr Cardiol Rev, 11(1):23-32. [cited by applicant]
Ryan, 2018, Identifying and Managing Hibernating Mycardium: What's New nad What Remains Unknown?, Current Heart Failure Reports, 15:214-223. [cited by applicant]
Sannino, 2009, Biodegradable Cellulose-based Hydrogels: Design and Applications, Materials, 2:353-373. [cited by applicant]